RAASi

Study compares kidney injury risk for COVID, flu patients

A Vanderbilt study found that renin-angiotensin-aldosterone system (RAASi) inhibitor drugs, which are commonly used to regulate high blood pressure, do not disproportionately increase the risk of acute kidney injury (AKI) in patients with COVID-19 compared to patients hospitalized with influenza.